Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection

Marcio L. Rodrigues, Li Shi, Eliana Barreto-Bergter, Leonardo Nimrichter, Sandra E. Farias, Elaine G. Rodrigues, Luiz R. Travassos, Joshua D. Nosanchuk

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly reduces host inflammation and prolongs the survival of mice lethally infected with C. neoformans, revealing a potential therapeutic strategy to control cryptococcosis.

Original languageEnglish (US)
Pages (from-to)1372-1376
Number of pages5
JournalClinical and Vaccine Immunology
Volume14
Issue number10
DOIs
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection'. Together they form a unique fingerprint.

  • Cite this

    Rodrigues, M. L., Shi, L., Barreto-Bergter, E., Nimrichter, L., Farias, S. E., Rodrigues, E. G., Travassos, L. R., & Nosanchuk, J. D. (2007). Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection. Clinical and Vaccine Immunology, 14(10), 1372-1376. https://doi.org/10.1128/CVI.00202-07